Rationale to invest: Jubilant Ingrevia was formed by spinning off the chemical and life science ingredients of Jubilant Life Sciences Ltd. The company derives 50% of its revenues from the life science chemicals division. The specialty chemicals and nutrition & health solution business account for 32% and 18% of revenues. We expect the company to post 18.3%/24.3%/33.9% CAGR growth in revenues/EBITDA/PAT over FY21-FY23 driven by strong growth in Life Science chemical and specialty chemical business.
